Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Phase 0 in Early Breast Cancer
NCT03197389Phase 1Completed
- Sponsor
- UZ Leuven
- Start
- Jan 2018
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in breast cancer (6 cohorts), sponsored by UZ Leuven. Primary endpoint: PD-1 Expression at 2 years. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03197389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197389.